Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
$310.67-14.59%
报价 2026-11-06
市值
$44.78B
EV
$55.51B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -28.7%
$182.65$436.00
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | -1.10 → -0.37 | — |
| FY+32028-12 | 1.5x | -1.10 → 1.27（扭亏） | 243.7 |
毛利率 65% · TTM 收入 $2909M · 基数 EPS -1.10（调整后）
电话会信号
辅助标签Q3 20262026-11-05
扩产需求加速上调指引盈利拐点
指引 上调
信心 5
分析师 4
“We are setting the goal to double revenues in the next 3 years, reaching $6 billion in revenue in 2029.”
原文引用（4）
- 扩产：we have accelerated a lot of investments in our pharma specific offerings, commercial team, and operations that drive both CapEx and operating expenses higher
- 需求加速：Over the last 9 months, we have seen a real surge in biopharma demand for our MRD technology, in clinical trials
- 上调指引：we are raising our full-year 2026 revenue guidance to a range of $3.05 billion to $3.35 billion up from the $2.85 billion to $2.91 billion
- 盈利拐点：it will be possible for us to continue to deliver another quarter of positive free cash flow and improving EBITDA in Q4
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NTRANatera, Inc. | $44.78B | -14.6% | +29.8% | 64.5% | – | – | 786.2x | |
| TEVATeva Pharmaceutical Industries Limited | $49.65B | +2.0% | -0.7% | 55.5% | 93.0x | 30.3x | 39.5x | |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| IQVIQVIA Holdings Inc. | $44.8B | +2.6% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| MTDMettler-Toledo International Inc. | $34.51B | +2.6% | +6.0% | 57.5% | 29.1x | 22.2x | 40.6x | |
| ILMNIllumina, Inc. | $32.23B | +2.5% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| PHGKoninklijke Philips N.V. | $29.66B | -0.5% | – | 45.2% | 24.5x | 10.1x | – | |
| DXCMDexCom, Inc. | $29.62B | -6.0% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| DGXQuest Diagnostics Incorporated | $28.21B | +0.3% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| 同行中位数 | – | – | +8.0% | 56.5% | 31.1x | 20.0x | 39.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $752.8M | $696.6M | $665.5M | $592.2M | $546.6M | $501.8M | $476.1M | $439.8M |
| Gross Margin | 64.5% | 64.8% | 67.1% | 64.9% | 63.5% | 63.2% | 62.9% | 61.8% |
| Operating Margin | -10.1% | -13.4% | -3.4% | -16.5% | -20.2% | -15.8% | -13.6% | -8.9% |
| Net Income | $-67M | $-85.1M | $47.3M | $-87.5M | $-100.9M | $-66.9M | $-53.8M | $-31.6M |
| Diluted EPS | -0.47 | -0.6 | 0.35 | -0.64 | -0.74 | -0.5 | -0.41 | -0.26 |
| Operating Cash Flow | $54.8M | $40.2M | $73.9M | $59.4M | $37.6M | $44.5M | $52.9M | $51.8M |